Manager Patient Advocacy BioPharma

Job description

メルクと一緒に、あなたの力を発揮しよう！ 冒険、限界への挑戦、そして発見に焦がれるあなたへ。あなたの大志を、メルクで羽ばたかせましょう！科学とテクノロジーを駆使したイノベーションに情熱を注ぐメルクのスタッフは世界中で活躍中です。ヘルスケア、生命科学、エレクトロニクスの分野で、メルクのソリューションは人々の暮らしをますます豊かなものにしています。あなたとメルクの力を合わせて、大きな夢を抱きましょう。メルクは、人、顧客、患者、そしてこの地球という惑星が共存する豊かな世界の構築に情熱を注いでいます。このためメルクでは、好奇心にあふれた人材を募集中です。メルクと一緒に、想像を超えた世界を開拓しませんか？ 患者さんのためにひとつになって団結し、生命の誕生、QOLの向上、命をつなぐサポートをすることか、ヘルスケアにおける私たちの目的です。私たちは、腫瘍学、神経学、不妊治療などの疾患領域において、医薬品、インテリジェント装置、革新的技術を開発します。私たちのチームは、人生のすべてのステージで患者さんを助けるために、情熱と執拗な好奇心を持って6大陸全体で協力して働いています。ヘルスケアチームに入ることは、多様的で包含的、そして柔軟な職場文化の一部となることです。世界中で個人的な能力開発とキャリアアップの素晴らしいチャンスが待ち受けています。 Job Description / 職務記述書 Patient Advocacy Manager Merck Biopharma Japan / メルクバイオファーマ株式会社 English Version Position Overview Item Details Title Patient Advocacy Manager Reporting to Head of Patient Advocacy (sole direct supervisor) Organizational structure Head of Market Access & Public Affairs → Head of Patient Advocacy → Patient Advocacy Manager Team Member of a four-person Market Access & Public Affairs team; no direct reports Department Market Access & Public Affairs Company Merck Biopharma Japan Place of work Tokyo, Japan Function / Area Patient Advocacy, Patient Policy & External Affairs Business scope Oncology, Fertility, Rare Tumours 1. Job Purpose / Mission The Patient Advocacy Manager contributes to patient advocacy and patient policy activities across Merck Biopharma Japan’s Oncology, Fertility, and Rare Tumours businesses, working closely with the Head of Patient Advocacy. As a member of the four-person Market Access & Public Affairs team, the role develops and executes patient-directed strategies that bring the patient voice into business and policy decisions while building trusted, compliant partnerships with patient organizations and other stakeholders. The Patient Advocacy Manager reports to the Head of Patient Advocacy and works in a matrix with Japan business-unit leaders and colleagues in Medical Affairs, Regulatory, Legal & Compliance, Communications, Commercial, and Clinical Operations. The role also partners closely with global Patient Advocacy and cross-functional colleagues to align local priorities with global strategies. The role has no direct reports and combines strategic planning, external engagement, policy advocacy, and hands-on execution. 2. Key Accountabilities & Responsibilities 2.1 Cross-Franchise Patient Advocacy Strategy and Implementation Contribute to the development and implementation of an integrated patient advocacy strategy across Oncology, Fertility, and Rare Tumours, with franchise-specific priorities reflecting different patient journeys, unmet needs, and stakeholder landscapes. Translate business and patient needs into annual advocacy plans, including priorities, milestones, KPIs, resource requirements, and budget, and maintain a clear view of the following year’s advocacy agenda. Act as a strategic and operational business partner to the Oncology, Fertility, and Rare Tumours leadership teams, ensuring that patient advocacy is embedded in launch planning, lifecycle planning, and relevant brand or indication plans. Prioritize activities across the three business areas while maintaining a coherent patient policy narrative and consistent standards of engagement. Liaise with Global Government & Public Affairs and Global Patient Advocacy colleagues to ensure strategic alignment between local and global priorities. 2.2 Patient Organization Partnerships and Patient Insights Build and maintain trusted, long-term, and compliant relationships with patient organizations and patient communities across Oncology, Fertility, and Rare Tumours. Identify unmet needs of patients and caregivers, barriers to diagnosis and treatment, quality-of-life impacts, and gaps in information or support; convert these insights into practical recommendations for internal teams and external engagement. Support capability-building and network development in rare-tumour communities where patient organizations are small, fragmented, or still emerging. Ensure that patient insights inform clinical development, evidence generation, value communication, HTA and reimbursement materials, launch planning, disease awareness, and access dialogues. 2.3 Patient Policy and External Engagement Contribute to day-to-day patient policy and advocacy engagement with patient organizations, academic societies, healthcare professionals, public institutions, policymakers, and other relevant stakeholders. Coordinate senior-level outreach with the Head of Market Access & Public Affairs, including engagement with public authorities, Diet members’ offices where appropriate, and relevant policy forums. Represent Merck Biopharma Japan in patient-focused, multi-stakeholder dialogues and contribute a balanced, evidence-based, patient-directed perspective to discussions on diagnosis, treatment access, care pathways, and outcomes. Develop clear patient-directed narratives and materials that translate scientific, regulatory, health-system, and access topics into language that is accurate and accessible to patients and non-specialist stakeholders. 2.4 Specified Intractable Disease Designation Activities: Rare Tumours and Priority Conditions Develop and execute advocacy activities supporting appropriate consideration of priority rare-tumour conditions, including desmoid tumours, in the context of Japan’s specified intractable disease designation process. Translate patient insights into a practical rare-tumour patient advocacy roadmap, including patient advisory boards, internal Get Closer activities, patient testimonials and patient-voice materials, localized disease-support and shared-decision-making resources, and appropriate disease-awareness activities. 2.5 Drug Pricing and Reimbursement System Advocacy Lead the patient advocacy contribution to policy discussions on Japan’s drug pricing, reimbursement, HTA, and patient-access systems, with particular attention to Oncology, Fertility, Rare Tumours, and other areas of high unmet need. For priority launches and policy topics, coordinate patient-directed value-evidence and HTA-readiness activities, including the Japanese adaptation of value models, systematic evidence review, patient and physician insights, and disease-burden and societal-impact evidence such as surgery avoidance and productivity impact. Liaise with Market Access & Pricing to monitor developments in the NHI drug-price system, reimbursement rules, HTA-related policy, rare-disease policy, and other reforms that may affect patient access and value recognition. Develop evidence-based, patient-directed policy positions and advocacy messages, incorporating patient experience, disease burden, clinical context, and access needs. Work with Market Access, Medical Affairs, Government Affairs, and industry-association colleagues to align positions, prepare stakeholder engagement, and support constructive dialogue with authorities and policymakers. Ensure that patient perspectives are appropriately reflected in value dossiers, policy submissions, access strategies, and pricing or reimbursement discussions. 2.6 Industry Association Leadership, Primarily EFPIA Participate in relevant pharmaceutical-industry activities, including initiatives led by EFPIA and JPMA, as well as broader industry-wide initiatives where relevant to and supportive of the patient advocacy and public affairs strategy. Serve as the primary internal point of contact for patient advocacy and relevant patient policy activities conducted through EFPIA and its Japan-related forums or working groups, as applicable. Represent or coordinate Merck Biopharma Japan’s participation in EFPIA working groups, consultations, position-paper development, evidence sharing, and joint advocacy initiatives, primarily in the areas of patient engagement, access, pricing, reimbursement, HTA, rare diseases, and healthcare policy. Coordinate positions and messages with regional and global Patient Advocacy, Market Access, Public Affairs, and policy teams, ensuring appr